You’ve seen the ads, heard the success stories, and maybe even watched a friend drop three dress sizes in a few months. The buzz around weight loss medications like Ozempic and Wegovy is impossible to ignore. But if you’ve done any digging, you know the struggle: your insurance might not cover it, your local pharmacy is out of stock, or the monthly price tag makes your eyes water. So, you start looking into telehealth companies—those sleek, direct-to-consumer platforms that promise convenience and affordability. One name that keeps popping up is Hers, the sister brand of Hims, known for making healthcare feel as easy as ordering a pizza. Naturally, you might wonder: does Hers offer tirzepatide, the active ingredient in blockbuster drugs like Mounjaro and Zepbound? It’s a fair question, especially since tirzepatide is currently the most talked-about tool for significant weight loss. Let’s cut through the noise and get you a clear, honest answer.

First, What Exactly Is Tirzepatide?

Before we dive into what Hers does and doesn’t sell, it helps to understand why tirzepatide is such a big deal. Think of it as a dual-action hormone mimic. Your body naturally produces hormones called GLP-1 and GIP that help regulate your appetite and blood sugar. Tirzepatide works by activating both of these pathways, which does two powerful things: it tells your brain you’re full much sooner, and it slows down how quickly your stomach empties food. The result? You eat less, feel satisfied longer, and your body processes sugar more efficiently. Originally approved as Mounjaro for type 2 diabetes, it quickly gained a second approval as Zepbound specifically for chronic weight management. Clinical trials showed people losing an average of 15-22% of their body weight, which is why demand has gone through the roof.

The Short Answer: What Hers Currently Offers

Here’s the straightforward truth: as of now, Hers does not offer tirzepatide in any form—neither the brand-name versions (Mounjaro, Zepbound) nor compounded versions. If you go to the Hers website and browse their weight loss offerings, you’ll find a different set of options. Their current lineup focuses on FDA-approved oral medications like metformin and bupropion-naltrexone (the combo known as Contrave), as well as injectable semaglutide, which is the active ingredient in Ozempic and Wegovy. So, if your heart is set on tirzepatide, Hers isn’t the answer right now. But don’t close this tab yet—the reasons behind this decision are actually quite interesting and might help you make a smarter choice for your own health journey.

Why Doesn’t Hers Carry Tirzepatide?

To understand Hers’ strategy, you have to look at the bigger picture of the weight loss drug market. Tirzepatide is newer than semaglutide, and its patent protection is still very strong. That means the only sources are the brand-name manufacturers (Eli Lilly) and compounding pharmacies that produce unapproved versions. Telehealth companies face a tricky legal and medical landscape here. Many large platforms, including Hers, have chosen to focus on semaglutide because it has a longer track record, more established supply chains, and clearer regulatory guidance. There’s also the issue of availability—tirzepatide has been in shortage for months, making it hard for any provider to guarantee consistent supply. Hers seems to be playing it safe and practical, building their program around medications they can reliably source and monitor.

What Hers Does Offer for Weight Loss (And How It Compares)

So, if you visit Hers for weight management, here’s what you’ll actually find:

  • Injectable semaglutide: This is their flagship weight loss offering. It works similarly to tirzepatide but only targets the GLP-1 pathway, not the GIP pathway. Clinical trials show average weight loss of about 12-15% of body weight with semaglutide—still impressive, though slightly less than tirzepatide’s 15-22%.
  • Oral medications: Options like metformin (an older diabetes drug) and bupropion-naltrexone (a combination that affects appetite centers in the brain). These are less potent than injectables but can be effective for some people, especially those who don’t want needles or have mild weight concerns.
  • Lifestyle support: Their program includes access to a care team, nutrition guidance, and progress tracking—basically, the wraparound services that make medication more effective.

The key difference? Semaglutide is a single-target drug, while tirzepatide is a dual-target drug. Think of it like this: semaglutide turns down the volume on your hunger, while tirzepatide turns down the volume and also rewires the signal. That dual action is why tirzepatide tends to produce slightly higher average weight loss. But for many people, semaglutide is more than enough to achieve meaningful results.

Should You Wait for Tirzepatide, or Go with What Hers Has?

This is the million-dollar question, and the answer depends entirely on your personal situation. If you have a significant amount of weight to lose (say, a BMI over 30 or over 27 with a weight-related condition), and you’re willing to navigate potential shortages and higher costs, tirzepatide might be worth pursuing through other channels—like your primary care doctor, an endocrinologist, or a different telehealth provider that does offer it. But if you’re looking for a solution that’s available now, with a proven track record and a streamlined process, Hers’ semaglutide program is a solid, evidence-based option. Many people lose 10-15% of their body weight on semaglutide, which is life-changing for most. Don’t let the search for the “perfect” drug delay you from starting a good one.

Practical Tips for Choosing Between Tirzepatide and Semaglutide

Here’s how to think about it like a savvy shopper:

  • Check your insurance first: Most insurance plans cover semaglutide (for diabetes) but not for weight loss. Tirzepatide is even less likely to be covered for weight purposes. Call your insurance and ask about coverage for both Zepbound and Wegovy—the answer might surprise you.
  • Consider your budget: Without insurance, brand-name tirzepatide can cost $1,000-$1,300 per month. Hers’ semaglutide program is typically more affordable, often around $199-$299 per month depending on the plan. Compounded versions of either drug can be cheaper but come with less regulatory oversight.
  • Think about side effects: Both drugs cause similar gastrointestinal side effects—nausea, vomiting, diarrhea, constipation. Some people find tirzepatide slightly easier to tolerate because the dual action allows for a gentler dose escalation, but everyone responds differently.
  • Don’t ignore the lifestyle piece: No medication works in a vacuum. Hers includes nutritional coaching and habit tracking, which can make a real difference in keeping weight off long-term. If you go with another provider, make sure they offer similar support.

What to Do Next

If you’re leaning toward Hers, start by filling out their online questionnaire. A healthcare provider will review your medical history and determine if you’re a candidate for semaglutide or one of their oral options. The process is quick and completely virtual—no waiting rooms, no awkward weigh-ins. If you’re set on tirzepatide, you’ll need to look elsewhere for now. Consider platforms like Ro, Sequence, or Push Health, which have been known to offer compounded tirzepatide, or book an appointment with a local obesity medicine specialist. Just be prepared for potential delays and higher out-of-pocket costs.

The Bottom Line

Does Hers offer tirzepatide? No, not at this time. But that doesn’t mean they can’t help you reach your weight loss goals. Their semaglutide program is a well-designed, accessible option for many people who are struggling with their weight and need a medically supervised, convenient solution. The most important thing is to start somewhere. Whether you choose Hers, another telehealth provider, or a traditional doctor, the best weight loss medication is the one you can actually get, afford, and stick with. Don’t let the perfect be the enemy of the good—if semaglutide is available today, it might be the right move for you.